AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05074810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avutometinib and sotorasib and defactinib
Description: The RP2D of avutometinib + sotorasib + defactinib determined in Part A will be used in Part B dose expansion
Study NCT05298358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RIC alloBMT w PTCy in refractory SSc
Description: The preparative regimen:~* Thymoglobulin 0.5 mg/kg IV day -9~* Thymoglobulin 2 mg/kg IV Days -8, -7~* Cyclophosphamide (Cy) 14.5 mg/kg IV Days -6,-5~* Fludarabine 30 mg/m2 IV Days -6, -5, -4, -3,-2~* Total body irradiation (TBI) 400cGy~* Day 0- infusion of unmanipulated bone marrow~The GVHD prophylaxis regimen:~* Cy 50 mg/kg IV Days 3, 4~* Tacrolimus (FK-506) (IV or oral (po)) beginning Day 5 with dose adjusted to maintain a trough level of 5-15 ng/mL. Sirolimus may be substituted for tacrolimus.~* Mycophenolate mofetil (MMF) 15 mg/kg po TID, maximum dose 1 g po TID Day 5 - Day 35~* Filgrastim (G-CSF) 5 µg/kg SQ daily beginning Day 5 until absolute neutrophil (ANC) is greater than 1000/µl over at least 2 days.~Supportive care:~* Mesna- 10 mg/kg/ IV Day 3, 4~* Patients will receive infection prophylaxis and treatment according to institutional guidelines.
Study NCT05566249 — intervention group
Intervention type: DEVICE
Intervention: ArtiSential
Description: Articulating laparoscopic instrument
Study NCT06797882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride- potassium iodide
Description: SDF , Riva Star, SDI Limited., Australia
Study NCT06797882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride varnish
Description: Duraphat varnish®, Colgate-Palmolive (UK) Ltd.
Study NCT06797882 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9 % saline
Description: Standard oral hygiene instructions every 3 months and application of Normal Saline for every 6 months
Study NCT06798220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Breakfast
Description: In this intervention, participants are offered a traditional breakfast (consisting of unprocessed or minimally processed foods), and postprandial appetite regulation is evaluated. Traditional breakfast includes chicken egg (boiled), white cheese (full-fat), white bread, black and green olives, tomatoes, cucumbers, and freshly squeezed orange juice.
Study NCT06798220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UPF Breakfast
Description: In this intervention, participants are offered an ultra-processed breakfast, and postprandial appetite regulation is evaluated. Ultra-processed breakfast includes pan-fried beef sausage (without oil), packaged sandwich bread, tomato-based ketchup, and packaged orange juice.
Study NCT05956314 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pharmacokinetics Assessments
Description: Blood samples for PK will be collected during screening (Days -14 to 0) at any time during the visit, or on Day 1 (up to 30 minutes prior to the first dose, if not performed during Screening) and on Day 7 and at End of Treatment (EoT, Cohort 1: Day 84; Cohort 2: Day 112) up to 30 minutes pre-dose and at 1 h, 2 h, 3 h, 6 h (+15 min) post-dose, on Days 28, 42, and 84 (for Cohort 2): 1 sample after the first dose, before the second dose, as late as possible in the visit, at End of Study (EoS, Cohort 1: Day 112; Cohort 2: Day 140), or at an ET visit: at any time during the visit.~* Altogether up to 15 samples, and approx. 30 mL of blood will be drawn for PK at screening or Day 1 and on Days 7, 28, 42, 84, EoT (84/112), and EoS (112/140), or at an ET visit, if applicable.~* Overall, up to a total of 85 mL of blood will be drawn during the trial for blood and PK assessments per patient in Cohort 1, and 95 mL of blood per patient in Cohort 2.
Study NCT05425446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous (SC) injection
Study NCT06799182 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periodontal treatment
Description: Based on the results of the dental examination and the diagnosis of the periodontal tissue condition according to the new classification of periodontal disease, we performed appropriate non-surgical treatment of periodontal disease, provided oral hygiene instruction, and took a biofilm sample from the deep periodontal pocket. We then collected a sample of the altered mucosa during bowel surgery for colorectal cancer and conducted a microbiological investigation using quantitative culture to compare the presence of Fusobacterium nucleatum and Porphyromonas gingivalis in the pariodontal pocket and altered intestinal mucosa.
Study NCT06798818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultra-rapid therapeutic hypothermia induction by total liquid ventilation
Description: Vent2Cool System is a targeted temperature management device used to induce ultra-rapid therapeutic hypothermia by total liquid ventilation.
Study NCT06797895 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: VR assisted mobility
Description: Commercially-based VR experience used to help move upper extremities to music, similar to dancing or Tai-Chi.
Study NCT06800118 — intervention group
Intervention type: DEVICE
Intervention: Music intervention
Description: Music will be played for patients undergoing coronary angiography, and vasospasm and pain levels will be evaluated.
Study NCT06799910 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continuous renal replacement therapy (CRRT)
Description: The patient is included in the study once they meet the eligibility criteria and as soon as the responsible physician has prescribed RRT according to the department's protocol. Randomization will be performed, and the patient will be assigned to either the standard or experimental groups.
Study NCT06799910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free UF Prescription
Description: The UF (ml/h) is prescribed by the responsible physician based on the patient's clinical, congestive, and hemodynamic status. The physician can implement the UF whenever necessary based on the patient's hemodynamic condition.
Study NCT06799312 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ipsilesional high frequency rTMS combined with physiotherapy
Description: As mentioned in details in arms description.
Study NCT06799312 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contralesional Continuous Burst Theta rTMS (cTBS) + Physiotherapy
Description: As mentioned in details in arms description.
Study NCT06799312 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS + Physiotherapy
Description: As mentioned in details in arms description.
Study NCT06799975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Patients in the education group will have a meeting with a physiotherapist at the end of the T1 evaluation, which will take place in a suitable room that ensures privacy is maintained. During this meeting, the physiotherapist will provide the patient with advice regarding their return home and will suggest simple exercises to activate/maintain the abdominal and lower back muscles, to be performed at home until the next visit, one month after the surgery. These exercises are part of standard clinical practice and should be routinely performed by patients who undergo lumbar spinal fusion in the period following the surgery. Additionally, the patient will have the opportunity to communicate, via email or phone, with the physiotherapist until the follow-up appointment with the spine surgeon (scheduled for one month later).
Study NCT06799975 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The usual discharge procedures consist of a brief interview with the neurosurgeon during which instructions are provided on how to manage the first month after the surgery.
Study NCT06799000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remibrutinib Dose A
Description: Remibrutinib Dose A (oral)
Study NCT06799000 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remibrutinib Dose B
Description: Remibrutinib Dose B (oral)
Study NCT06799000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remibrutinib Dose B
Description: Remibrutinib Dose B (oral)
Study NCT06799000 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1
Description: Placebo matching to remibrutinib Dose A (oral)
Study NCT06799000 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2
Description: Placebo matching to remibrutinib Dose B (oral)
Study NCT06799832 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: urethal perfusion index monitoring
Description: The urethral perfusion index will be monitored using the IKORUS System (Vygon, Écouen, France)
Study NCT06798532 — intervention group
Intervention type: OTHER
Intervention: Collection of data from the patient's medical file.
Description: Collection of data from the patient's medical file.
Study NCT06799650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gammora®
Description: Gammora® SC + Tenofovir/3TC + darunavir+ritonavir
Study NCT06799208 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopy
Description: Minimal invasive approach. Have peritoneal tissue sparing character . Minimal blood loss . Reduction of postoperative adhesions.
Study NCT06798415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Intralesional metronidazole (5 mg/ml, 100 ml, Flagyl®, Sanofi, France) will be injected into each lesion based on its size (5 mg/cm2). The infiltration of intralesional dose will be given once weekly for up to 6 weeks. Treatment will be stopped in patients cured before 6 weeks of treatment, and patients were only asked to come for lesion assessment. A fine insulin needle will be used to infiltrate the lesion.~The lesion will be thoroughly infiltrated with the drug solution until the base will be completely blanched. Depending on the lesion size, the amount of solution required ranged from 0.2 to 4.0 ml per lesion. No local anesthesia will be added. The solutions will be injected intralesionally and not subcutaneously.
Study NCT06798285 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars Plana Vitrectomy Standard
Description: Group I: PPV with endoillumination set at 3.2 Lm.
Study NCT06798285 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars Plana Vitrectomy 3D
Description: Group II: PPV with endoillumination set at 0.5 Lm.
Study NCT06798038 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Description: 35 Patients will be undergo for radiofrequency ablation which will be applied to each genicular nerve.
Study NCT06798038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenol neurolysis
Description: 35 Patients will be administered with 2.0 ml of 6% phenol solution prepared from crystallized phenol per genicular nerve
Study NCT06798038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alcohol neurolysis
Description: 35 Patients will be administered with 1.0ml of 70% alcohol per genicular nerve
Study NCT06170385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Each physical therapy session will commence with a 5-minute warm-up, with fun activities to mobilize the joints and activate the muscles, using the videos available in the HEAL-ME platform. The warm-up session will be followed by a 20 to 40-min program with tailored activities and games comprising jumping, squatting, skipping, balancing, and jogging. The session will finish with a 5-minute cool down with stretching exercises and a relaxation video from the HEAL-ME platform.
Study NCT06798402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (BAYO9867)
Description: Intralesional ciprofloxacin (2 mg/ml, 100 ml, Ciproxin®, Bayer Schering pharma AG, Germany), each lesion was injected based on lesion size (2 mg/cm2).
Study NCT06798402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium stibogluconate (Pentostam)
Description: Intralesional sodium stibogluconate (100 mg/ml, 100 ml vial, Pentostam®, GlaxoSmithKline, UK), each lesion was injected based on lesion size (1 mg/cm2)
Study NCT06799390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular Vagus Nerve Stimulation
Description: Transcutaneous auricular vagal nerve stimulation
Study NCT06799390 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Auricular Vagus nerve Stimulation
Description: Transcutaneous auricular vagal nerve ear clip applied without current
Study NCT06799364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 28-days consumption of Product A in 45 to 60-year-old healthy subjects.
Description: 40 healthy volunteers will consume Product A twice per day during 28 consecutive days.
Study NCT06799364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 28-days consumption of Product B in 45 to 60-year-old healthy subjects.
Description: 40 healthy volunteers will consume Product B twice per day during 28 consecutive days.
Study NCT06799364 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 28-days consumption of Control product in 45 to 60-year-old healthy subjects.
Description: 40 healthy volunteers will consume Control product twice per day during 28 consecutive days.
Study NCT06800079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EBT
Description: Elastic Band Resistance Training
Study NCT06799715 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: 33.5g sucrose dissolved in 300mL tap water
Study NCT06799715 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 33.5g glucose dissolved in 300mL tap water
Study NCT06799715 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fructose
Description: 33.5g fructose dissolved in 300mL tap water
Study NCT06799715 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 300mL water
Study NCT06799611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM336 Injection
Description: subcutaneous CM336 administration step-up dosing Dose and frequency of CM336 according to the protocol
Study NCT05956314 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Clinical global impression of severity (CGI-S)
Description: Lesions severity will be assessed using the CGI-S scale, which is a 5-point scale (from 0= none to 4= very severe) modified from Busner et al. 2007 (30) by the investigator during screening and on Days 1 (baseline, prior to first dosing), 7, 28, 42, 63, 84, 112, 140, and at ET visit - where applicable, per cohort).~The clinician scoring takes into account all available information, including a knowledge of the patient's history, psychosocial circumstances, symptoms (pain), behaviour, and the impact of the symptoms on the patient's ability to function (ability to walk). investigators will complete the CGI-S at various timepoints based on the question. Please choose the response that best describes your assessment of the disease severity, based upon the totality of information available to you
Study NCT05956314 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS) pain scale
Description: The patient will enter the PPPK- or PC-related pain score (not any pain) using a VAS pain scale in the patient-reported diary, on a weekly basis starting on Day 1 through ET visit, prior to the second administration of the IMP (evening dose) at the same time every time (±1 hour) except for Day 1 (Visit 2, in-clinic visit), where the assessment will be performed pre-dose during the visit.~The score will be collected on every in-clinic visit during the treatment and follow up periods (Days 1, 7, 28, 42, 63, 84, 112, 140, and at an ET visit - where applicable, per cohort).~The following parameter will be evaluated on a VAS from 0 (no pain) to 100 (severe intolerable pain) based on the question:~How was your worst pain intensity in the past 24 hours?
Study NCT05956314 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Peak pruritus-numerical rating scale (PP-NRS)
Description: The peak pruritus severity will be assessed using the PP-NRS, an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The PP-NRS will be entered by the patients on a weekly basis starting on Day 1 through ET visit, preferably after the evening dose, at the same time every time (±1 hour) except for Day 1 (Visit 2, in-clinic visit), where the assessment will be performed pre-dose during the visit.~The scores will be collected on every in-clinic visit during the treatment and follow up periods (Days 1, 7, 28, 42, 63, 84, 112, and 140, or at an ET visit - where applicable, per cohort).~The PP-NRS was designed to measure peak pruritus, or worst itch, over the previous 24 hours based on the following question: On scale from 0 (no itch) to 10 (worst imaginable itch) how was your worst itch in the past 24 hours?
Study NCT05956314 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Patient global impression of change (PGI-C) scoring
Description: The PGI will be evaluated on Days 1, 7, 28, 42, 63, 84, 112, and 140, or at an ET visit - where applicable, per cohort.~The PGI-C will be evaluated using a 7-point scale from 1 (very much improved) to 7 (very much worse) as follows:~Since the start of the trial, my overall status has:~from, 1= very much improved to 7= very much worse
Study NCT06799793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GI Genius
Description: GI Genius software component is an artificial intelligence-based medical device that has been trained to process colonoscopy images containing regions consistent with colorectal lesions such as polyps, including those with flat morphology (nonpolyp).
Study NCT06799793 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Colonscope Olympus
Description: Colonoscopy with one of the Olympus colonoscopes supplied to the IRCCS AOUBO Gastroenterology Unit without the aid of the CAD system
Study NCT05956314 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Patient global impression of severity (PGI-S) scoring
Description: The PGI will be evaluated on Days 1, 7, 28, 42, 63, 84, 112, and 140, or at an ET visit - where applicable, per cohort.~The PGI-S will be evaluated using a 5-point scale from 1 (none) to 5 (very severe) as follows:~Please rate the severity of your disease right now, from 1= none to 5= very severe
Study NCT05956314 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lesion photography
Description: High quality photographic documentation of the treated lesions will be performed during Screening and on Days 1, 7, 42, 63, 84, 112, and 140, or at an ET visit before treatment - where applicable, per cohort.~The photographs will be taken under standardised conditions, using imitoMeasure (Ⓒ imito AG 2016-2022).
Study NCT05956314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KM-001 cream 1% 16 weeks treatment.
Description: KM-001 1% will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. The patient will use IMP twice a day for 112 days. IMP will be applied on the plantar surfaces.
Study NCT06379685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-190
Description: Propylene glycol 0.3% - Polyethylene glycol 400 0.3%. Ophthalmic solution.
Study NCT06379685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systane Ultra®
Description: Propylene glycol 0.3% - Polyethylene glycol 400 0.4%. Ophthalmic solution.
Study NCT06799507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interventions Based on Mindfulness
Description: Affirmation, Relaxation, Mindfulness, Meditation, Healthy Lifestyle, Quality Life
Study NCT06799507 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine clinical procedure
Description: Routine clinical procedure
Study NCT06798493 — intervention group
Intervention type: OTHER
Intervention: Complex Regional Pain Syndrome (CRPS) Severity Score - Self Report
Description: Self-report tool in a questionnaire format to capture CPRS Severity Score.
Study NCT05465018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Happy Flow / Baseline
Description: Baseline (without make-up or mask)
Study NCT06454383 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06454383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Description: Given PO
Study NCT06454383 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05465018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Make-up
Description: To test device on participant who is wearing facial make-up
Study NCT05465018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sunglasses
Description: To test device on participant who is wearing sunglasses
Study NCT05465018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Face mask
Description: To test device on participant who is wearing a facial mask
Study NCT05465018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimum requirements camera
Description: To test the minimum requirements of the camera